Development in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma Treatment

Cancer Biother Radiopharm. 2024 Oct;39(8):551-561. doi: 10.1089/cbr.2024.0078. Epub 2024 Aug 2.

Abstract

Malignant peritoneal mesothelioma (MPeM) is a rare primary malignant tumor originating from peritoneal mesothelial cells. Insufficient specificity of the symptoms and their frequent reappearance following surgery make it challenging to diagnose, creating a need for more efficient treatment options. Natural killer cells (NK cells) are part of the innate immune system and are classified as lymphoid cells. Under the regulation of activating and inhibiting receptors, NK cells secrete various cytokines to exert cytotoxic effects and participate in antiforeign body, antiviral, and antitumor activities. This review provides a comprehensive summary of the specific alterations observed in NK cells following MPeM treatment, including changes in cell number, subpopulation distribution, active receptors, and cytotoxicity. In addition, we summarize the impact of various therapeutic interventions, such as chemotherapy, immunotherapy, and targeted therapy, on NK cell function post-MPeM treatment.

Keywords: immunotherapy; malignant peritoneal mesothelioma; malignant pleural mesothelioma; natural killer cells; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy / methods
  • Killer Cells, Natural* / immunology
  • Mesothelioma, Malignant* / immunology
  • Mesothelioma, Malignant* / pathology
  • Mesothelioma, Malignant* / therapy
  • Peritoneal Neoplasms* / immunology
  • Peritoneal Neoplasms* / therapy